Literature DB >> 17907234

Multicenter validation of a new quality of life measure in pediatric lupus.

L Nandini Moorthy1, Margaret G E Peterson, Maria Baratelli, Melanie J Harrison, Karen B Onel, Elizabeth C Chalom, Kathleen Haines, Philip J Hashkes, Thomas J A Lehman.   

Abstract

OBJECTIVE: Pediatric systemic lupus erythematosus (SLE) is a chronic fluctuating disease that significantly impacts quality of life (QOL). There is no pediatric SLE-specific health-related QOL (HRQOL) scale. Our objective was to develop and validate a new pediatric SLE-specific HRQOL scale.
METHODS: We developed the Simple Measure of the Impact of Lupus Erythematosus in Youngsters (SMILEY) based on results of qualitative research of children with SLE and their parents. SMILEY has parallel child and parent reports with a 5-faces scale for responses. SMILEY comprises 4 domains: effect on self, limitations, social, and burden of SLE. In this cross-sectional study, we examined face, content, construct, and concurrent validity; internal consistency; test-retest reliability; and child-parent agreement for SMILEY. Children </=18 years of age with SLE and their parents completed corresponding child and parent SMILEY reports, as well as other QOL and physical function scales. Qualified physicians assessed SLE activity, damage, and severity.
RESULTS: Eighty-six children with SLE and 80 parents participated. SMILEY was found to have face, content, construct, and concurrent validity (Spearman's rank correlation [r(s)] >/=0.4); test-retest reliability (intraclass correlation coefficient [ICC] 0.9); and internal consistency (alpha = 0.9). Moderate agreement was found between child and parent SMILEY reports (ICC 0.7, r(s) = 0.5, P < 0.001).
CONCLUSION: SMILEY is a brief, easily understood, valid, and reliable pediatric SLE-specific QOL scale. Because SMILEY assesses children's self-perception of QOL as impacted by SLE, we predict that it will have great utility in clinical practice, clinical trials, and outcomes research.

Entities:  

Mesh:

Year:  2007        PMID: 17907234     DOI: 10.1002/art.22988

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

Review 1.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 2.  Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues.

Authors:  Sergio M A Toloza; Meenakshi Jolly; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 3.  Pediatric SLE--towards a comprehensive management plan.

Authors:  Hermine I Brunner; Jennifer Huggins; Marisa S Klein-Gitelman
Journal:  Nat Rev Rheumatol       Date:  2011-03-08       Impact factor: 20.543

Review 4.  Assessing Patient-Reported Outcomes in Pediatric Rheumatic Diseases: Considerations and Future Directions.

Authors:  Christina K Zigler; Rachel L Randell; Bryce B Reeve
Journal:  Rheum Dis Clin North Am       Date:  2022-02       Impact factor: 2.032

5.  Validation of Patient-Reported Outcomes Measurement Information System Short Forms for Use in Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Jordan T Jones; Adam C Carle; Janet Wootton; Brianna Liberio; Jiha Lee; Laura E Schanberg; Jun Ying; Esi Morgan DeWitt; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-28       Impact factor: 4.794

Review 6.  Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.

Authors:  Erkan Demirkaya; Alessandro Consolaro; Hafize Emine Sonmez; Gabriella Giancane; Dogan Simsek; Angelo Ravelli
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

7.  Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration.

Authors:  Lakshmi Nandini Moorthy; Elizabeth Roy; Vamsi Kurra; Margaret G E Peterson; Afton L Hassett; Thomas J A Lehman; Christiaan Scott; Dalia El-Ghoneimy; Shereen Saad; Reem El Feky; Sulaiman Al-Mayouf; Pavla Dolezalova; Hana Malcova; Troels Herlin; Susan Nielsen; Nico Wulffraat; Annet van Royen; Stephen D Marks; Alexandre Belot; Jurgen Brunner; Christian Huemer; Ivan Foeldvari; Gerd Horneff; Traudel Saurenman; Silke Schroeder; Polyxeni Pratsidou-Gertsi; Maria Trachana; Yosef Uziel; Amita Aggarwal; Tamas Constantin; Rolando Cimaz; Theresa Giani; Luca Cantarini; Fernanda Falcini; Silvia Magni Manzoni; Angelo Ravelli; Donato Rigante; Fracnceso Zulian; Takako Miyamae; Shumpei Yokota; Juliana Sato; Claudia S Magalhaes; Claudio A Len; Simone Appenzeller; Sheila Oliveira Knupp; Marta Cristine Rodrigues; Flavio Sztajnbok; Rozana Gasparello de Almeida; Adriana Almeida de Jesus; Lucia Maria de Arruda Campos; Clovis Silva; Calin Lazar; Gordana Susic; Tadej Avcin; Ruben Cuttica; Ruben Burgos-Vargas; Enrique Faugier; Jordi Anton; Consuelo Modesto; Liza Vazquez; Lilliana Barillas; Laura Barinstein; Gary Sterba; Irama Maldonado; Seza Ozen; Ozgur Kasapcopur; Erkan Demirkaya; Susa Benseler
Journal:  Pediatr Rheumatol Online J       Date:  2014-11-25       Impact factor: 3.054

8.  Lupus Erythematosus Quality of Life Questionnaire (LEQoL): Development and Psychometric Properties.

Authors:  Elena Castellano-Rioja; María Del Carmen Giménez-Espert; Ana Soto-Rubio
Journal:  Int J Environ Res Public Health       Date:  2020-11-20       Impact factor: 3.390

9.  Physical function assessment tools in pediatric rheumatology.

Authors:  Lakshmi Nandini Moorthy; Margaret Ge Peterson; Melanie J Harrison; Karen B Onel; Thomas Ja Lehman
Journal:  Pediatr Rheumatol Online J       Date:  2008-06-04       Impact factor: 3.054

10.  Improvement of medication adherence in adolescents and young adults with SLE using web-based education with and without a social media intervention, a pilot study.

Authors:  Lisabeth V Scalzi; Christopher S Hollenbeak; Emily Mascuilli; Nancy Olsen
Journal:  Pediatr Rheumatol Online J       Date:  2018-03-14       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.